tocilizumab in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
1.04 [0.77 ; 1.41 ] CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 5 8% 1,335 moderate not evaluable deathsdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.94 [0.72 ; 1.23 ] CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 7 29% 2,230 moderate not evaluable deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
1.04 [0.78 ; 1.38 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Talaschian, 2021 3 0% 1,132 moderate not evaluable clinical deteriorationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
0.56 [0.26 ; 1.20 ] CORIMUNO-TOCI-1 (Group 1), 2020 1 0% 130 NA not evaluable clinical improvementdetailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
1.44 [1.06 ; 1.96 ] COVACTA (Rosas), 2020, REMAP-CAP (tocilizumab), 2021 2 44% 1,193 moderate not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
1.19 [0.81 ; 1.75 ] COVACTA (Rosas), 2020 1 0% 438 NA not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Veiga, 2021 1.54 [0.65; 3.63]
0.96 [0.65 ; 1.43 ] CORIMUNO-TOCI-1 (Group 1), 2020, Rosas (REMDACTA), 2021, Veiga, 2021 3 26% 909 moderate not evaluable hospital dischargedetailed results Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
0.97 [0.79 ; 1.20 ] Rosas (REMDACTA), 2021 1 0% 649 NA not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
0.67 [0.39 ; 1.14 ] COVACTA (Rosas), 2020 1 0% 273 NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
0.48 [0.25 ; 0.94 ] COVACTA (Rosas), 2020 1 0% 191 NA not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
0.90 [0.65 ; 1.23 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 4 19% 1,245 moderate not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Veiga, 2021 1.65 [0.81; 3.37]
1.21 [0.87 ; 1.67 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Veiga, 2021 3 21% 1,209 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 16:03 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
